The Expression And Clinc Pathological Significance Of MAGE-A3?NY-ESO-1 And SP17 Antigen In NSCLC And Adjacent Tissues

ObjectiveTo detect the expression and manifestation of MAGE-A3?NY-ESO-1?Sp 17 in no-small cell lung carcinoma cases and their adjacent tissues, through analyzing the connection of these three indexes and clinical indexes,to provide a more meaningful theoretical foundation for clinical immunotherapy.Methods1.We performed a retrospective analysis of 54 patients who underwent thoracic surgery of non-small cell lung cancer in Binzhou Medical University Affiliated Hospital and confirmed by pathological examination between January 2011 to December 2011;while collecting their archived paraffin of 54 cancer tissue and 10 adjacent tissues.2.Using Envision immunohistochemical staining to detect of the expression of MAGE-A3? NY-ESO-1 and Sp17 antigen in 54 cases of NSCLC and 10 cases of adjacent tissues.3.According to the result of follow-up visit to research the relationship of these three indexes with the clinical pathological features and disease prognosis.4.To research the correlation of the expressin of the three indexes in non-small cell lung carcinoma each other.Results1.Of 54 NSCLC patients, the positive expression rates of MAGE-A3? NY-ESO-1 and Sp17 in tumor tissues were 50%(27/54),44.44%(24/54),88.89%(48/54),in 10 adjacent tissues were 10%(1/10)?0%(0/10)?20%(2/10),the difference was statistically significant(P<0.05).2.MAGE-A3 is associated with gender, lymphatic metastasis, tumor histological type and stage(P<0.05). NY-ESO-1 is affected by stage, histopathological differentiation and tumor histological type(P<0.05). Sp17 is relate to lymphatic metastasis, histopathological differentiation and stage (P<0.05).3.The five years' morbidities of MAGE-A3 and Sp17 positive patients in NSCLC are shorter than their negative patients, but NY-ESO-1 positive patients shows longer survival than NY-ESO-1 negative patients.4.MAGE-A3, NY-ESO-1 and Sp 17 has no collection between each other.ConclusionAccording to the results of the research, MAGE-A3?NY-ESO-1 and Sp 17 have the important collection with the occurrence, development and prognosis in NSCLC. They are the valuable targets for development of immunotherapy against the positive expression of non-small cell lung carcinoma.